These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 16857825)

  • 1. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
    Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA; Lynch TJ
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
    Patel JD; Pasche B; Argiris A
    Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of EGFR inhibition in the treatment of non-small cell lung cancer.
    Ray M; Salgia R; Vokes EE
    Oncologist; 2009 Nov; 14(11):1116-30. PubMed ID: 19892771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
    Maione P; Gridelli C; Troiani T; Ciardiello F
    Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
    Cascone T; Gridelli C; Ciardiello F
    Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer.
    Agelaki S; Georgoulias V
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):855-74. PubMed ID: 16262567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes.
    Wheatley-Price P; Shepherd FA
    Curr Opin Oncol; 2008 Mar; 20(2):162-75. PubMed ID: 18300766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies.
    Patel JD
    Curr Opin Oncol; 2006 Nov; 18(6):609-14. PubMed ID: 16988582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HKI-272 in non small cell lung cancer.
    Wong KK
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4593-6. PubMed ID: 17671147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?
    Dziadziuszko R; Hirsch FR; Varella-Garcia M; Bunn PA
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4409s-4415s. PubMed ID: 16857819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New antiangiogenetic agents and non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P
    Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR-directed therapies to treat non-small-cell lung cancer.
    Ho C; Laskin J
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1133-45. PubMed ID: 19572809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
    Crawford J
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
    Bunn PA; Thatcher N
    Oncologist; 2008; 13 Suppl 1():37-46. PubMed ID: 18263773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
    Bunn PA; Thatcher N
    Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer.
    Khalil MY; Grandis JR; Shin DM
    Expert Rev Anticancer Ther; 2003 Jun; 3(3):367-80. PubMed ID: 12820779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.
    Doebele RC; Oton AB; Peled N; Camidge DR; Bunn PA
    Lung Cancer; 2010 Jul; 69(1):1-12. PubMed ID: 20092908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.